Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

  • S. Alonso, M. Riveiro-Barciela, I. Fernandez, D. Rincón, Y. Real, S. Llerena, F. Gea, A. Olveira, C. Fernandez-Carrillo, B. Polo, J. A. Carrión, A. Gómez, M. J. Devesa, C. Baliellas, Á. Castro, J. Ampuero, R. Granados, J. M. Pascasio, A. Rubín, J. Salmeron, E. Badia, J. M. M. Planas, S. Lens, J. Turnes, J. L. Montero, M. Buti, R. Esteban, C. M. Fernández-Rodríguez
  • Journal of Viral Hepatitis, December 2016, Wiley
  • DOI: 10.1111/jvh.12648

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1111/jvh.12648

In partnership with: